Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — J.P. Morgan Healthcare Conference 2010
5 slides from Jazz Pharmaceuticals's conference presentation, Jan 20, 2010
Slide 1: Relevant slides from Jazz Pharmaceuticals' presentation at J.P. Morgan Healthcare Conference
Exhibit 99.1 Relevant J.P. January Morgan 14, slides 2010 Healthcare from Jazz Conference Pharmaceuticals’ by Bruce presentation Cozadd, Chairman at the & CEO
Slide 2: Forward-Looking Statements
Forward-Looking 2 This Pharmaceuticals’ matters, potential expectations timing risks of manufacturers; to cash performance elsewhere Registration Exchange forward-looking “Safe expectations. Jazz successfully itsPharmaceuticals Pharmaceuticals’ flow presentation and Xyrem® Harbor” ofand upside uncer
Slide 3: Reconciliation of GAAP to Adjusted EPS and 2010 Guidance
Reconciliation 2009 1Q09 2010 Low Intangible Add: Stock-based Non-cash Contract Deduct: Diluted * contingencies, Actual Jazz 21ThePharmaceuticals High Quarterly Guidance* 2Q09 2010 results GAAP adjusted revenues interest asset financial 3Q09 compensation for many of net Actual amortization net Adjus
Slide 4: Products, Adjusted EPS and Stock Price Performance
$35 Products $30 $25 1Q09 Adjusted $0.10 EPS -$0.10 Positive Programs -$0.40 -$0.30 NDA JAZZ $12 $6 $4 $2 Jan-09 * intangible presentation Jazz 3 Adjusted 4X Increase $0Luvox Xyrem (millions) $10 Pharmaceuticals 3Q09 submitted 2Q09 $0.00 Stock Adjusted Mar-09 Adjusted data $8 EPS* assets, diluted CR
Slide 5: Presentation transcript
Relevant 11:00am 28th Westin San [Bruce So products look cash-flow revenues we’re pipeline, significance. our position I’m stock Francisco, Annual atgoing Cozadd, the going St. became in PST, announcing to portion price EPS, Francis bottom 2009 give to J.P. And toJanuary talk California graph, so CE
Jazz Pharmaceuticals — J.P. Morgan Healthcare Conference 2010 on 6ix